价格

ASTRAZENECA PTY LTD

L 4 66-82 Talavera Rd, Macquarie Park, New South Wales, 澳大利亚

别名:

focus pharmaceuticals

概览

试验阶段分布

阶段

试验数

占比

不适用

100.0%

试验状态分布

终止

100.0%

药物批准

按机构分类的批准

NMPA

National Medical Products Administration

药物批准

TGA

Therapeutic Goods Administration

220

药物批准

近期批准

KAVIGALE, sipavibart, 300 mg in 2 mL (150 mg/mL), Solution for injection/infusion vial. (459773)

TGA

2025-05-22

KAVIGALE, sipavibart, 300 mg in 2 mL (150 mg/mL), Solution for injection/infusion vial. (459773)

TGA

2025-05-22

DATROWAY datopotamab deruxtecan 100 mg powder for injection vial (444066)

TGA

2025-05-20

DATROWAY datopotamab deruxtecan 100 mg powder for injection vial (444066)

TGA

2025-05-20

Tezspire tezepelumab 210 mg in 1.91mL solution for Injection prefilled pen (432812)

TGA

2025-03-24

Tezspire, tezepelumab 210 mg in 1.91mL solution for Injection prefilled syringe (427956)

TGA

2025-03-24

Tezspire tezepelumab 210 mg in 1.91mL solution for Injection prefilled pen (432812)

TGA

2025-03-24

Tezspire, tezepelumab 210 mg in 1.91mL solution for Injection prefilled syringe (427956)

TGA

2025-03-24

Acalabrutinib Maleate Tablets

NMPA

2024-10-29

ARX-Ticagrelor ticagrelor 90 mg tablet blister pack (445790)

TGA

2024-08-07

资讯

暂无资讯文章

返回机构列表

ASTRAZENECA PTY LTD

概览

试验阶段分布

试验状态分布

相关临床试验

该机构主办的试验（1）

A Blood Diagnostic test for epidermal growth factor receptor (EGFR) mutations

药物批准

按机构分类的批准

近期批准

资讯